What's Happening?
Four U.S. states—California, New Hampshire, Pennsylvania, and South Carolina—ceased Medicaid coverage for GLP-1 medications approved for weight loss on January 1, 2026. This decision was driven by concerns over the high cost of these drugs. A study published
in JAMA revealed that following this policy change, prescriptions for weight-loss GLP-1s in these four states plummeted by 84% relative to states that maintained coverage. Specifically, quarterly prescriptions per 100,000 Medicaid beneficiaries in the affected states dropped from 2,914 to 421 between the final quarter of 2025 and the first quarter of 2026. Lead author Bryant Shuey, an assistant professor of medicine at the University of Pittsburgh, noted that this change could mean between 175,500 and 526,600 fewer beneficiaries filling these prescriptions across the four states.
Why It's Important?
This policy change and its immediate impact highlight the critical role of insurance coverage in access to essential medications, particularly for high-cost treatments like GLP-1s for weight loss. The dramatic decline in prescriptions indicates that many Medicaid beneficiaries in these states have lost access to a treatment that can significantly aid in weight management. This is important because discontinuing GLP-1s often leads to weight regain and worsening cardiometabolic risk factors, as evidenced by trials like Surmount-4. The decision by these states, while aimed at cost containment, creates a significant disparity in healthcare access, where individuals with sufficient financial resources can continue treatment by paying out-of-pocket, while those reliant on Medicaid cannot. This exacerbates health inequities and could lead to poorer health outcomes for vulnerable populations.
What's Next?
The long-term consequences of this policy are yet to be fully understood, but experts anticipate potential health setbacks for affected individuals, including weight regain and increased risks for conditions like diabetes. Patients who have lost coverage are advised to consult their clinicians about alternative weight management strategies, such as covered medications, diet counseling, and structured weight-loss or diabetes prevention programs. The study did not measure health outcomes or privately paid prescriptions, so the full scope of impact on individual patients' health is still being assessed. This situation may prompt further debate at state and federal levels regarding Medicaid coverage for weight-loss drugs, balancing cost concerns with public health needs and equitable access to care.
Beyond the Headlines
The decision by these four states to cut Medicaid coverage for weight-loss GLP-1s reflects a broader tension within the U.S. healthcare system: the balance between controlling healthcare costs and ensuring access to effective treatments. While GLP-1s are highly effective, their high price tag presents a significant challenge for state budgets, particularly for programs like Medicaid that serve low-income populations. This situation raises ethical questions about who bears the cost of innovative but expensive medications and how society prioritizes health interventions. It also underscores the need for comprehensive strategies that address obesity, including prevention, lifestyle interventions, and affordable access to medical treatments, rather than solely relying on medication. The disparity created by these coverage changes could deepen existing health inequalities, making it harder for those with fewer resources to manage chronic conditions effectively.

















